Padmaja Ketineni Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5211 Marsh Rd, Okemos, MI 48864 Phone: 517-319-1383 |
Amanda P Zullo, OTRL Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2378 Woodlake Dr Ste 280, Okemos, MI 48864 Phone: 517-706-0421 Fax: 517-706-0423 |
Marissa Friday Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3860 Dobie Rd, Okemos, MI 48864 Phone: 517-381-6100 |
Monique Renee Jorae Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2378 Woodlake Dr Ste 280, Okemos, MI 48864 Phone: 517-706-0421 |
Olivia Hicks Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2378 Woodlake Dr Ste 240, Okemos, MI 48864 Phone: 517-706-0421 |
Stephanie Westenfeld Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5211 Marsh Rd, Okemos, MI 48864 Phone: 517-319-1383 Fax: 517-318-0258 |
Mrs. Sarah Platt Cooney, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3544 Meridian Crossings, Suite 160, Okemos, MI 48864 Phone: 517-347-2495 |
Carmen Slenk Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5211 Marsh Rd, Okemos, MI 48864 Phone: 517-319-1383 Fax: 517-318-0258 |
News Archive
Each dollar a state spends on mental health care cuts roughly 25 cents off its jail expenditures by reducing its inmate population, a new study shows.
The Center for Global Health Policy's "Science Speaks" blog profiles Sens. Barbara Mikulski (D-Md.), Patty Murray (D-Wash.), and Richard Shelby (R-Ala.), discusses their different committee appointments, and examines their support for global health initiatives.
The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for SilenorĀ® (doxepin) for the treatment of insomnia.
› Verified 6 days ago